Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 5Recruiting 4Active not recruiting 3Not yet recruiting 2Withdrawn 1Unknown 1Terminated 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1NET 1Gynecologic 1Genitourinary 1Endocrine 1

Conditions

Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

somapacitan 1irinotecan sucrosofate 1PM 01183 1Injections 1Fluorodeoxyglucose F18 1Diagnostic Self Evaluation 1Carboplatin 1Cabergoline 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × Carboplatin × Endocrine × Clear all
NCT05385861 2025-08-15

Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET

National Health Research Institutes, Taiwan

Phase 1/2 Enrolling by invitation
52 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡